Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7336 to 7350 of 7708 results

  1. Pembrolizumab–vibostolimab with etoposide and platinum-based chemotherapy for untreated extensive-stage small-cell lung cancer [ID6361]

    In development [GID-TA11401] Expected publication date: TBC

  2. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis (TA27)

    This guidance has been replaced by NICE guideline CG59 and NICE guideline CG79.

  3. Psoriatic arthritis in adults: certolizumab pegol (ESNM42)

    This evidence summary has been updated and replaced by NICE technology appraisal guidance 445.

  4. Durvalumab for adjuvant treatment of resectable non-small-cell lung cancer [ID1263]

    In development [GID-TA11569] Expected publication date: TBC

  5. Atezolizumab with chemotherapy for untreated recurrent or advanced endometrial cancer [ID6417]

    Discontinued [GID-TA11522]

  6. Atezolizumab for adjuvant treatment of high-risk locally advanced squamous cell head and neck cancer [ID4052]

    In development [GID-TA10933] Expected publication date: TBC

  7. Sacituzumab govitecan for treating unresectable metastatic urothelial cancer [ID6150]

    In development [GID-TA11009] Expected publication date: TBC

  8. Intrapartum care for healthy women and babies - rectal examination after delivery

    Discontinued [GID-NG10395]

  9. Violence and aggression: short-term management in mental health, health and community settings

    Discontinued [GID-NG10397]

  10. Common mental health problems: identification and pathways to care (CG123)

    We withdrew this guideline in May 2024, because all of the recommendations are now covered in other NICE guidelines, or are out of date and no longer relevant to clinical practice. For guidance on common mental health problems, see our guidelines on:

  11. The MAGEC system for spinal lengthening in children with scoliosis (MTG18)

    August 2024: Following the lifting on the UK suspension of MAGEC system (modified MAGEC X system), NICE's prioritisation board will be reviewing the guidance that was withdrawn in April 2020. We will update this page once a decision is made.

  12. Peezy Midstream for urine collection (MT446)

    In development [GID-MT538] Expected publication date: TBC

  13. Peezy Midstream for urine collection (MIB183)

    NICE has withdrawn the med tech innovation briefing (MIB) on Peezy Midstream for urine collection because there is published evidence that shows it offers no clinical benefits over standard care (clean catch method).

  14. Insertion of a balloon device to disimpact an engaged fetal head before an emergency caesarean section (IPG515)

    September 2024: We have withdrawn this guidance. This is because the main evidence that the guidance was based on has been retracted by the journal. New NICE interventional procedures guidance is in development and the expected publication date is April 2025. Please see NICE's in-development webpage on balloon disimpaction of the baby’s head at emergency caesarean during the second stage of labour. In the meantime, please read the NIHR updated process to oversee the safe introduction of new procedures (PDF only).